<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="4671">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01654302</url>
  </required_header>
  <id_info>
    <org_study_id>STU00061115</org_study_id>
    <nct_id>NCT01654302</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Synera in Osteoarthritis Pain</brief_title>
  <official_title>Efficacy and Safety of Synera in OA Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Thomas J. Schnitzer</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Nuvo Research Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Northwestern University</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Knee osteoarthritis (OA) can result in significant pain and limitation of function.  A
      number of topical non-steroidal anti-inflammatory drugs have been shown to reduce pain in
      this condition.  This study examines a different topical approach, utilizing a topical
      anesthetic agent, to evaluate if application of such an agent would provide relief of
      exercise-induced knee pain in people with knee OA.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">October 2014</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>knee pain scores on a numeric rating scale (NRS)</measure>
    <time_frame>during the 5 minutes after exercise</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>composite arthritis score on the Western Ontario and McMaster Universities Arthritis Index (WOMAC)</measure>
    <time_frame>1 and 5 minutes, 12 hours and 1 day after exercise</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life on the Short Form 12 (SF12)</measure>
    <time_frame>1 and 5 minutes, 12 hours and 1 day after exercise</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pain quality on the Pain Quality Assessment Scale (PQAS)</measure>
    <time_frame>1 and 5 minutes, 12 hours and 1 day after exercise</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Knee Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>Synera</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Inactive Patch</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>70 mg lidocaine/ 70 mg tetracaine topical patch</intervention_name>
    <description>70 mg lidocaine/ 70 mg tetracaine topical patch applied once for 12 hours</description>
    <arm_group_label>Synera</arm_group_label>
    <other_name>Synera</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo</description>
    <arm_group_label>Inactive Patch</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Men and women, age 40 years and above

          2. Meet American College of Rheumatology criteria for knee OA

          3. Knee pain most days of the week for the past month

          4. Knee pain &gt; 5/10 after exercise intervention

          5. Capable of undertaking exercise intervention

          6. Stable cardiovascular function

          7. Able to return for all clinic visits

          8. Able to read and understand the informed consent document

        Exclusion Criteria:

          1. Use of a walker to ambulate or inability to ambulate

          2. Other forms of arthritis

          3. Other major causes of pain that could be expected to interfere with assessment of
             pain during this trial, e.g., recurrent migraine, back pain, fibromyalgia

          4. History of myocardial infarction

          5. Blood Pressure &gt; 140 systolic/100 diastolic

          6. Scheduled for and likely to need joint replacement surgery in the next 3 months

          7. Any medical condition that in the judgment of the investigator would make the
             participant not suitable for the study

          8. Sensitivity to lidocaine, topical or injectable analgesics/anesthetics.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas J Schnitzer, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northwestern University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Julia Marks</last_name>
    <phone>312-503-1215</phone>
    <email>julia.marks@northwestern.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julia Marks</last_name>
      <phone>312-503-1215</phone>
      <email>julia.marks@northwestern.edu</email>
    </contact>
    <investigator>
      <last_name>Thomas J Schnitzer, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 18, 2014</lastchanged_date>
  <firstreceived_date>July 11, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Northwestern University</investigator_affiliation>
    <investigator_full_name>Thomas J. Schnitzer</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Tetracaine</mesh_term>
    <mesh_term>Lidocaine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
